{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TRAW","limit":50},"count":50,"signals":[{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ved an additional annual retainer of $15,000, $10,000 and $8,000, respectively, in addition to the retainer received for service as a member of such committee.  All amounts are paid in quarterly installments. To the extent that an individual serves as a non-employee director for less than a full year, he or she shall be entitled to receive a pro-rata portion of the above amounts based on thepercentag","filed_date":"2025-10-08","accession":"0001104659-25-097926","full_text":"https://origin.rootz.global/static/filing/0001104659-25-097926.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"onsider and vote upon the amendment and restatement of the Companys 2021 Incentive Compensation Plan, as amended and restated;  3. To approve, on a non-binding advisory basis, the compensation of our named executive officers;  4. To approve, on a non-binding advisory basis, the frequency of holding an advisory vote to approve the compensation of our named executive officers;  5. To consider and vote upon the ratificatio","filed_date":"2025-10-08","accession":"0001104659-25-097926","full_text":"https://origin.rootz.global/static/filing/0001104659-25-097926.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"| | Victor Moyo, M.D. | | | 57 | | | Chief Medical Officer, Oncology | | Iain Dukes, D. Phil. Please see Dr. Dukes biography under the section entitled Directors, above. Nora Brennan.Ms. Brennan was appointed Interim Chief Financial Officer of the Company on February 5, 2025. Ms. Brennan has served on management teams of various publicly traded and private life science companies, raising more than $2 billion in capital, building finance","filed_date":"2025-04-30","accession":"0001558370-25-006013","full_text":"https://origin.rootz.global/static/filing/0001558370-25-006013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us. 24 [Table of Contents](#TOC) Other Special Regulatory Procedures *Animal Rule* In 2002, the FDA amended its requirements applicable to NDAs to permit the approval of certain drugs and biologic","filed_date":"2025-03-31","accession":"0001558370-25-004165","full_text":"https://origin.rootz.global/static/filing/0001558370-25-004165.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"such term in Section 3(v). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. 2 Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Net Proceeds shall have the meaning ascribed to such term","filed_date":"2025-03-10","accession":"0001104659-25-022193","full_text":"https://origin.rootz.global/static/filing/0001104659-25-022193.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"and vote upon the Amendment and Restatement of the 2021 Incentive Compensation Plan (the Incentive PlanProposal);  |  |  | |  |  |  |  |  3. To approve, on an advisory basis, the compensation of our named executive officers;  |  |  | |  |  |  |  |  4. To consider and vote upon the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024;","filed_date":"2024-10-11","accession":"0001104659-24-107822","full_text":"https://origin.rootz.global/static/filing/0001104659-24-107822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval.  Failure to follow the FDAs applicable regulatory requirements may result in enforcement action.  Changes in product candidate manufacturing or formulation may resu","filed_date":"2024-08-09","accession":"0001104659-24-087458","full_text":"https://origin.rootz.global/static/filing/0001104659-24-087458.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us. Other Special Regulatory Procedures *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 i","filed_date":"2024-04-01","accession":"0001558370-24-004525","full_text":"https://origin.rootz.global/static/filing/0001558370-24-004525.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified;  |  |  | |  |  |  |  |  2. To approve, on an advisory basis, the compensation of our named executive officers;  |  |  | |  |  |  |  |  3. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December3","filed_date":"2023-06-07","accession":"0001104659-23-068911","full_text":"https://origin.rootz.global/static/filing/0001104659-23-068911.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us. Other Special Regulatory Procedures *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 i","filed_date":"2023-03-30","accession":"0001558370-23-005107","full_text":"https://origin.rootz.global/static/filing/0001558370-23-005107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"and vote upon the Amendment and Restatement of the 2021 Incentive Compensation Plan (the Incentive PlanProposal);  |  |  | |  |  |  |  |  3. To approve, on an advisory basis, the compensation of our named executive officers;  |  |  | |  |  |  |  |  4. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December3","filed_date":"2022-05-25","accession":"0001104659-22-064708","full_text":"https://origin.rootz.global/static/filing/0001104659-22-064708.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us. Other Special Regulatory Procedures *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 i","filed_date":"2022-03-21","accession":"0001558370-22-004015","full_text":"https://origin.rootz.global/static/filing/0001558370-22-004015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ith the offer and sale of the Shares contemplated hereby, and any such rights so disclosed have either been fully complied with by the Company or effectively waived by the holders thereof. 4 (ix)* No Material Adverse Effect*. The Company and each of its Subsidiaries (a complete list of the Subsidiaries is included as Schedule 4 hereto) has been duly organized and validly exists as a corporation, partnership or limited l","filed_date":"2021-08-20","accession":"0001104659-21-108245","full_text":"https://origin.rootz.global/static/filing/0001104659-21-108245.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"| |  |  |  |  |  2. To consider and vote upon the 2021 Incentive Compensation Plan (the Incentive PlanProposal);  |  |  | |  |  |  |  |  3. To approve, on an advisory basis, the compensation of our named executive officers;.  |  |  | |  |  |  |  |  4. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December","filed_date":"2021-05-28","accession":"0001104659-21-074323","full_text":"https://origin.rootz.global/static/filing/0001104659-21-074323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  Other Special Regulatory Procedures  Orphan Drug Designation  The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000","filed_date":"2021-03-18","accession":"0001104659-21-038452","full_text":"https://origin.rootz.global/static/filing/0001104659-21-038452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"|  3. |  |  To consider and vote upon the Amendment and Restatement of the 2018 Omnibus Incentive Compensation Plan; |  | |  |  |  4. |  |  To approve, on an advisory basis, the compensation of our named executive officers;. |  | |  |  |  5. |  |  To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31,","filed_date":"2020-04-23","accession":"0001047469-20-002532","full_text":"https://origin.rootz.global/static/filing/0001047469-20-002532.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"g expenses, future revenues, capital requirements and needs for additional financing;  the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;  our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and com","filed_date":"2020-03-27","accession":"0001047469-20-001878","full_text":"https://origin.rootz.global/static/filing/0001047469-20-001878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2020-03-27","accession":"0001047469-20-001878","full_text":"https://origin.rootz.global/static/filing/0001047469-20-001878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ng expenses, future revenues, capital requirements and needs for additional financing; the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials; our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and comm","filed_date":"2019-11-12","accession":"0001104659-19-062715","full_text":"https://origin.rootz.global/static/filing/0001104659-19-062715.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $1.60, subject to adju","filed_date":"2019-09-25","accession":"0001104659-19-051271","full_text":"https://origin.rootz.global/static/filing/0001104659-19-051271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ng expenses, future revenues, capital requirements and needs for additional financing; the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials; our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and comm","filed_date":"2019-08-14","accession":"0001104659-19-045963","full_text":"https://origin.rootz.global/static/filing/0001104659-19-045963.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders equity or results of operations of the Company or prevent or materi","filed_date":"2019-05-17","accession":"0001104659-19-030304","full_text":"https://origin.rootz.global/static/filing/0001104659-19-030304.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ng expenses, future revenues, capital requirements and needs for additional financing; the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials; our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and comm","filed_date":"2019-05-15","accession":"0001104659-19-029745","full_text":"https://origin.rootz.global/static/filing/0001104659-19-029745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":54,"context":"f Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019; |  | |  |  |  4. |  |  To approve, on an advisory basis, the compensation of our named executive officers; |  | |  |  |  5. |  |  To approve, on an advisory basis, the frequency of advisory votes on the compensation of our named executive officers; and |  | |  |  |  6. |  |  To transact such other busin","filed_date":"2019-04-29","accession":"0001047469-19-002692","full_text":"https://origin.rootz.global/static/filing/0001047469-19-002692.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"g expenses, future revenues, capital requirements and needs for additional financing;  the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;  our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and com","filed_date":"2019-04-01","accession":"0001047469-19-001839","full_text":"https://origin.rootz.global/static/filing/0001047469-19-001839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"under existing contracts, exclusion from Federal healthcare programs, corporate integrity agreements, consent decrees, or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2019-04-01","accession":"0001047469-19-001839","full_text":"https://origin.rootz.global/static/filing/0001047469-19-001839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"to being named in this Proxy Statement and to serve as a director if elected. In the event any nominee for director declines or is unable to serve, the proxies may be voted for a substitute nominee selected by the Board of Directors.  **THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE \"FOR\"****ALL****NOMINEES.** All of our directors bring to our Board of Directors executive leadership experience from their service as execut","filed_date":"2018-06-08","accession":"0001047469-18-004342","full_text":"https://origin.rootz.global/static/filing/0001047469-18-004342.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"g expenses, future revenues, capital requirements and needs for additional financing;  the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;  our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and com","filed_date":"2018-03-16","accession":"0001047469-18-001777","full_text":"https://origin.rootz.global/static/filing/0001047469-18-001777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"tribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2018-03-16","accession":"0001047469-18-001777","full_text":"https://origin.rootz.global/static/filing/0001047469-18-001777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ng expenses, future revenues, capital requirements and needs for additional financing; the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials; our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and comm","filed_date":"2017-08-14","accession":"0001104659-17-051848","full_text":"https://origin.rootz.global/static/filing/0001104659-17-051848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"to being named in this Proxy Statement and to serve as a director if elected. In the event any nominee for director declines or is unable to serve, the proxies may be voted for a substitute nominee selected by the Board of Directors.  **THE BOARD OF DIRECTORS RECOMMENDS A VOTE \"FOR\"****ALL****NOMINEES.** All of our directors bring to our Board of Directors executive leadership experience from their service as executives and/or","filed_date":"2017-04-12","accession":"0001047469-17-002552","full_text":"https://origin.rootz.global/static/filing/0001047469-17-002552.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"g expenses, future revenues, capital requirements and needs for additional financing;  the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;  our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and com","filed_date":"2017-03-29","accession":"0001047469-17-002146","full_text":"https://origin.rootz.global/static/filing/0001047469-17-002146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"tribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2017-03-29","accession":"0001047469-17-002146","full_text":"https://origin.rootz.global/static/filing/0001047469-17-002146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ts any business so as to require such qualification, except where the failure to be so qualified in any such jurisdiction would not reasonably be expected to, individually or in the aggregate, have a material adverse effect on the assets, business, operations, financial condition, stockholders equity or results of operations of the Company and the Subsidiaries (as defined below) taken as a whole (a Material Adverse Effe","filed_date":"2016-12-05","accession":"0001104659-16-160513","full_text":"https://origin.rootz.global/static/filing/0001104659-16-160513.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"perties and to conduct the businesses in which it is engaged, except where the absence of such power or authority (either individually and in the aggregate) could not reasonably be expected to have a material adverse effect on: (i) the business, condition (financial or otherwise), results of operations, shareholders equity, properties or prospects (as such prospects are disclosed or described in the Prospectus) of the C","filed_date":"2016-07-13","accession":"0001104659-16-132420","full_text":"https://origin.rootz.global/static/filing/0001104659-16-132420.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"to being named in this Proxy Statement and to serve as a director if elected. In the event any nominee for director declines or is unable to serve, the proxies may be voted for a substitute nominee selected by the Board of Directors.  **THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR****ALL****NOMINEES.** All of our directors bring to our Board of Directors executive leadership experience from their service as executives and/or di","filed_date":"2016-04-13","accession":"0001047469-16-012162","full_text":"https://origin.rootz.global/static/filing/0001047469-16-012162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"g expenses, future revenues, capital requirements and needs for additional financing;  the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;  our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies,, for funding and co","filed_date":"2016-03-28","accession":"0001047469-16-011628","full_text":"https://origin.rootz.global/static/filing/0001047469-16-011628.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"tribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2016-03-28","accession":"0001047469-16-011628","full_text":"https://origin.rootz.global/static/filing/0001047469-16-011628.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"vent Radford from serving as an independent consultant to the compensation committee.  The compensation committee has reviewed our compensation policies and practices for all employees, including our named executive officers, as they relate to risk management practices and risk-taking incentives, and has determined that there are no risks arising from these policies and practices that are reasonably likely to have a mat","filed_date":"2016-03-28","accession":"0001047469-16-011628","full_text":"https://origin.rootz.global/static/filing/0001047469-16-011628.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"respond to, previous treatment with hypomethylating agents, or HMAs, within the first nine months of initiation of HMA treatment, and had their last dose of HMA therapy within six months prior to enrollment in the trial. The primary endpoint of this study is overall survival, and an interim analysis is anticipated. This randomized trial of approximately 225 patients is expected to be conducted at abo","filed_date":"2015-11-12","accession":"0001104659-15-078285","full_text":"https://origin.rootz.global/static/filing/0001104659-15-078285.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"to being named in this Proxy Statement and to serve as a director if elected. In the event any nominee for director declines or is unable to serve, the proxies may be voted for a substitute nominee selected by the Board of Directors.  **THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR****ALL****NOMINEES.** All of our directors bring to our Board of Directors executive leadership experience from their service as executives and/or di","filed_date":"2015-04-29","accession":"0001047469-15-004101","full_text":"https://origin.rootz.global/static/filing/0001047469-15-004101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"tribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2015-03-30","accession":"0001047469-15-002952","full_text":"https://origin.rootz.global/static/filing/0001047469-15-002952.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"to being named in this Proxy Statement and to serve as a director if elected. In the event any nominee for director declines or is unable to serve, the proxies may be voted for a substitute nominee selected by the Board of Directors. 2 **Table of Contents THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ALL NOMINEES.** All of our directors bring to our Board of Directors executive leadership experience from their service as executi","filed_date":"2014-04-29","accession":"0001104659-14-031546","full_text":"https://origin.rootz.global/static/filing/0001104659-14-031546.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"nsfusions to alleviate their anemia. Total number of patients, entry criteria, secondary endpoints, and the statistical analysis plan will be finalized during the SPA process. We project to start enrollment in the Phase 3 study in the second half of 2014 at multiple sites in the United States and Europe. We are also evaluating a prognostic tool based on genomic methylation analysis in this patient po","filed_date":"2014-03-20","accession":"0001047469-14-002718","full_text":"https://origin.rootz.global/static/filing/0001047469-14-002718.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"tribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.  **Other Special Regulatory Procedures** *Orphan Drug Designation* The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,","filed_date":"2014-03-20","accession":"0001047469-14-002718","full_text":"https://origin.rootz.global/static/filing/0001047469-14-002718.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"future revenues, capital requirements and needs for additional financing; |  | |  | | the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials; |  | |  | | our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for fund","filed_date":"2020-05-15","accession":"0001104659-20-062608","full_text":"https://origin.rootz.global/static/filing/0001104659-20-062608.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ONTIME trial, a protocol for a randomized controlled trial in a more homogeneous patient population is being developed. Pending regulatory approvals and appropriate financing, we hope to initiate enrollment in this trial as early as the second half of 2015. In light of the regulatory guidance, we stopped patient accrual in our 04-24 single-arm clinical trial of rigosertib IV in higher-risk MDS during","filed_date":"2015-03-30","accession":"0001047469-15-002952","full_text":"https://origin.rootz.global/static/filing/0001047469-15-002952.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":93,"match_count":6,"context":"and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on the Companys business, results of operations and financial condition. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on te","filed_date":"2024-11-14","accession":"0001558370-24-015752","full_text":"https://origin.rootz.global/static/filing/0001558370-24-015752.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":88,"match_count":6,"context":"and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on the Companys business, results of operations and financial condition. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on te","filed_date":"2025-11-13","accession":"0001104659-25-110845","full_text":"https://origin.rootz.global/static/filing/0001104659-25-110845.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TRAW","company":"Traws Pharma, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ves an additional annual retainer of $15,000, $10,000 and $8,000, respectively, in addition to the retainer received for service as a member of such committee.  All amounts are paid in quarterly installments.  All of our directors are eligible to receive additional discretionary awards under our 2021 Incentive Compensation Plan, subject to the annual limit set forth in such plan.  We reimburse each n","filed_date":"2024-10-11","accession":"0001104659-24-107822","full_text":"https://origin.rootz.global/static/filing/0001104659-24-107822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"fe466a91dc51edaccf9a99d492d6dace19825dbd584af513ff95853b6091da23","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"d1fd442bd3d967ea684dc3cae5f5749558f5a28d8d17f43b1a64e87aea07e874","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":47,"hourly_limit":500,"remaining":453,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}